These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32214713)

  • 1. Genome sequence variation analysis of two SARS coronavirus isolates after passage in Vero cell culture.
    Jin W; Hu L; Du Z; Gao Q; Gao H; Ning Y; Feng J; Zhang J; Yin W; Li N
    Chin Sci Bull; 2004; 49(17):1824-1827. PubMed ID: 32214713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational dynamics of the SARS coronavirus in cell culture and human populations isolated in 2003.
    Vega VB; Ruan Y; Liu J; Lee WH; Wei CL; Se-Thoe SY; Tang KF; Zhang T; Kolatkar PR; Ooi EE; Ling AE; Stanton LW; Long PM; Liu ET
    BMC Infect Dis; 2004 Sep; 4():32. PubMed ID: 15347429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.
    Cavanagh D
    Avian Pathol; 2003 Dec; 32(6):567-82. PubMed ID: 14676007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A persistently replicating SARS-CoV-2 variant derived from an asymptomatic individual.
    Caccuri F; Zani A; Messali S; Giovanetti M; Bugatti A; Campisi G; Filippini F; Scaltriti E; Ciccozzi M; Fiorentini S; Caruso A
    J Transl Med; 2020 Sep; 18(1):362. PubMed ID: 32967693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
    Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q
    Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.
    Zhang CH; Guo ZM; Zheng HY; Lu JH; Wang YF; Yan XG; Zhao Y; DU XW; Zhang X; Fang L; Ling WH; Qi SY; Yu XB; Zhong NS
    Chin Med J (Engl); 2004 Nov; 117(11):1625-9. PubMed ID: 15569476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe acute respiratory syndrome coronavirus persistence in Vero cells.
    Palacios G; Jabado O; Renwick N; Briese T; Lipkin WI
    Chin Med J (Engl); 2005 Mar; 118(6):451-9. PubMed ID: 15788125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt.
    Saleh AA; Saad MA; Ryan I; Amin M; Shindy MI; Hassan WA; Samir M; Khattab AA; Abdelgayed SS; Seadawy MG; Fahmy HM; Amer K
    Antib Ther; 2021 Jul; 4(3):135-143. PubMed ID: 34286215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and Identification of a Rare Spike Gene Double-Deletion SARS-CoV-2 Variant From the Patient With High Cycle Threshold Value.
    Liu LT; Tsai JJ; Chen CH; Lin PC; Tsai CY; Tsai YY; Hsu MC; Chuang WL; Chang JM; Hwang SJ; Chong IW
    Front Med (Lausanne); 2021; 8():822633. PubMed ID: 35071285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation analysis of the severe acute respiratory syndrome coronavirus putative non-structural protein 2 gene and construction of three-dimensional model.
    Lu JH; Zhang DM; Wang GL; Guo ZM; Zhang CH; Tan BY; Ouyang LP; Lin L; Liu YM; Chen WQ; Ling WH; Yu XB; Zhong NS
    Chin Med J (Engl); 2005 May; 118(9):707-13. PubMed ID: 15899130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification, propagation and molecular characterization of SARS-CoV-2 delta variant isolated from Egyptian COVID-19 patients.
    Alotaibi B; El-Masry TA; Seadawy MG; El-Harty BE; Saleh A; Gad AF; El-Hosseny MF; Mahran YF; El-Bouseary MM
    Infect Genet Evol; 2022 Jun; 100():105278. PubMed ID: 35367360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers.
    Neuman BW; Stein DA; Kroeker AD; Churchill MJ; Kim AM; Kuhn P; Dawson P; Moulton HM; Bestwick RK; Iversen PL; Buchmeier MJ
    J Virol; 2005 Aug; 79(15):9665-76. PubMed ID: 16014928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 variants reveal features critical for replication in primary human cells.
    Pohl MO; Busnadiego I; Kufner V; Glas I; Karakus U; Schmutz S; Zaheri M; Abela I; Trkola A; Huber M; Stertz S; Hale BG
    PLoS Biol; 2021 Mar; 19(3):e3001006. PubMed ID: 33760807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
    Spruth M; Kistner O; Savidis-Dacho H; Hitter E; Crowe B; Gerencer M; Brühl P; Grillberger L; Reiter M; Tauer C; Mundt W; Barrett PN
    Vaccine; 2006 Jan; 24(5):652-61. PubMed ID: 16214268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of SARS-CoV-2 Evolution in Paediatric Primary Airway Epithelial Cell Cultures Compared with Vero-Derived Cell Lines.
    Bamford CGG; Broadbent L; Aranday-Cortes E; McCabe M; McKenna J; Courtney DG; Touzelet O; Ali A; Roberts G; Lopez Campos G; Simpson D; McCaughey C; Fairley D; Mills K; Power UF; On Behalf Of The Breathing Together Investigators
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice.
    Liu MQ; Jiang RD; Guo J; Chen Y; Yang DS; Wang X; Lin HF; Li A; Li B; Hu B; Wang ZJ; Yang XL; Shi ZL
    J Virol; 2022 Apr; 96(8):e0016922. PubMed ID: 35343762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct sequencing of SARS-coronavirus S and N genes from clinical specimens shows limited variation.
    Tong S; Lingappa JR; Chen Q; Shu B; LaMonte AC; Cook BT; Birge C; Chern SW; Liu X; Galloway R; Mai le Q; Ng WF; Yang JY; Butany J; Comer JA; Monroe SS; Beard SR; Ksiazek TG; Erdman D; Rota PA; Pallansch MA; Anderson LJ
    J Infect Dis; 2004 Sep; 190(6):1127-31. PubMed ID: 15319863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
    Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
    Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.